Filip Tudor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Filip Tudor has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Blažen Marijić
Department of Otorhinolaryngology, Head and Neck Surgery, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia
7 shared publications - Ita Hadžisejdić
Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia
5 shared publications - Boban M. Erovic
Institute of Head and Neck Diseases, Evangelical Hospital, 1180 Vienna, Austria
3 shared publications - Emina Babarović
Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia
3 shared publications - Diana Maržić
Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia
2 shared publications Ita Hadžisejdić
Medicinski fakultet Sveučilišta u Rijeci, Zavod za opću patologiju i patološku anatomiju
2 shared publications
Latest Publications
- Open Access
Spatial Remodeling of the Immune Microenvironment During Laryngeal Carcinogenesis Reveals Prognostic Immune Patterns in Laryngeal Squamous Cell Carcinoma
Background/Objectives: Despite therapeutic advances, laryngeal squamous cell carcinoma (LSCC) remains a clinical challenge. We investigated immune microenvironment remodeling and its prognostic relevance during laryngeal carcinogenesis. Methods: This retrospective study included 227 patients: 45 with benign laryngeal polyps, 55 with laryngeal epithelial dysplasia, and 127 with LSCC; 55 (43.3%) LSCCs were Union for International Cancer Control (UICC) stage I–II and 72 (56.7%) stage III–IV. Immunohistochemistry on tissue microarrays (TMAs) was used to assess the density of cluster of differentiation (CD)4-, CD8-, forkhead box P3 (FOXP3)-, programmed cell death protein 1 (PD-1)-, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-, CD68-, and CD163-positive immune cells, together with FOXP3/CTLA-4 double-positive cells. Immune-cell densities were expressed as the percentage of the respective intraepithelial/intratumoral or stromal compartment occupied by positively stained immune cells. An exploratory Protective Immune Score (PIS; 0–2) assigned one point each for high intraepithelial FOXP3 and high stromal CTLA-4 cell density. Results: LSCC showed increased stromal immune-cell density and coordinated immune organization. Stromal PD-1 correlated with CD4, CD8, and FOXP3 density (rs = 0.561, 0.515, and 0.403), and stromal CTLA-4 with FOXP3 (rs = 0.556; all p < 0.0001). High intraepithelial FOXP3 was associated with improved disease-specific survival (DSS; hazard ratio [HR] = 0.26, 95% confidence interval [CI] 0.10–0.72) and disease-free survival (DFS; HR = 0.24, 95% CI 0.10–0.59). High stromal CTLA-4 similarly favored DSS (HR = 0.29, 95% CI 0.11–0.74) and DFS (HR = 0.26, 95% CI 0.11–0.61). The PIS remained independently associated with DSS (adjusted HR = 0.29, 95% CI 0.16–0.55) and DFS (adjusted HR = 0.29, 95% CI 0.17–0.52). Conclusions: Laryngeal carcinogenesis is characterized by progressive, compartment-specific immune remodeling, with the stroma emerging as the principal site of coordinated immune organization. The PIS captures spatially defined favorable immune features and warrants validation in independent cohorts.
Open AccessSpatial Remodeling of the Immune Microenvironment During Laryngeal Carcinogenesis Reveals Prognostic Immune Patterns in Laryngeal Squamous Cell Carcinoma
Background/Objectives: Despite therapeutic advances, laryngeal squamous cell carcinoma (LSCC) remains a clinical challenge. We investigated immune microenvironment remodeling and its prognostic relevance during laryngeal carcinogenesis. Methods: This retrospective study included 227 patients: 45 with benign laryngeal polyps, 55 with laryngeal epithelial dysplasia, and 127 with LSCC; 55 (43.3%) LSCCs were Union for International Cancer Control (UICC) stage I–II and 72 (56.7%) stage III–IV. Immunohistochemistry on tissue microarrays (TMAs) was used to assess the density of cluster of differentiation (CD)4-, CD8-, forkhead box P3 (FOXP3)-, programmed cell death protein 1 (PD-1)-, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-, CD68-, and CD163-positive immune cells, together with FOXP3/CTLA-4 double-positive cells. Immune-cell densities were expressed as the percentage of the respective intraepithelial/intratumoral or stromal compartment occupied by positively stained immune cells. An exploratory Protective Immune Score (PIS; 0–2) assigned one point each for high intraepithelial FOXP3 and high stromal CTLA-4 cell density. Results: LSCC showed increased stromal immune-cell density and coordinated immune organization. Stromal PD-1 correlated with CD4, CD8, and FOXP3 density (rs = 0.561, 0.515, and 0.403), and stromal CTLA-4 with FOXP3 (rs = 0.556; all p < 0.0001). High intraepithelial FOXP3 was associated with improved disease-specific survival (DSS; hazard ratio [HR] = 0.26, 95% confidence interval [CI] 0.10–0.72) and disease-free survival (DFS; HR = 0.24, 95% CI 0.10–0.59). High stromal CTLA-4 similarly favored DSS (HR = 0.29, 95% CI 0.11–0.74) and DFS (HR = 0.26, 95% CI 0.11–0.61). The PIS remained independently associated with DSS (adjusted HR = 0.29, 95% CI 0.16–0.55) and DFS (adjusted HR = 0.29, 95% CI 0.17–0.52). Conclusions: Laryngeal carcinogenesis is characterized by progressive, compartment-specific immune remodeling, with the stroma emerging as the principal site of coordinated immune organization. The PIS captures spatially defined favorable immune features and warrants validation in independent cohorts.
- Open Access
- 12 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7195
PD-L1 Expression and Immune Microenvironment Remodeling During Laryngeal Carcinogenesis: Implications for Malignant Progression of Laryngeal Dysplasia
Laryngeal dysplasia (LD) is the principal precursor of laryngeal squamous cell carcinoma (LSCC), but reliable biomarkers predicting malignant transformation remain unavailable. This study investigated programmed death-ligand 1 (PD-L1) expression and immune microenvironment remodeling during laryngeal carcinogenesis. Immunohistochemical analysis of PD-L1, CD4, CD8, CD68, and CD163 was performed in 36 benign lesions, 41 LDs, and 102 LSCCs. PD-L1 expression was assessed using the combined positive score (CPS) and tumor proportion score (TPS), while immune cell infiltration was quantified in the intraepithelial and stromal compartments and across the entire tissue specimen. PD-L1 expression and infiltration of all investigated immune cell populations increased progressively from benign lesions through dysplasia to invasive carcinoma. High-grade dysplasia exhibited significantly greater CD4 infiltration in all compartments and increased stromal CD8 and CD163 infiltration than low-grade dysplasia. PD-L1 expression positively correlated with intraepithelial CD163 and stromal CD8 infiltration. Although no biomarker independently distinguished progressive from non-progressive dysplasia, overall CD4, intraepithelial and overall CD68, and stromal CD163 were associated with progression risk. Immune microenvironment remodeling begins during the dysplastic stage of laryngeal carcinogenesis. These findings may improve risk stratification of laryngeal dysplasia and support the development of immunopreventive and immune-targeted therapeutic strategies.
- 12 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7195
Open AccessPD-L1 Expression and Immune Microenvironment Remodeling During Laryngeal Carcinogenesis: Implications for Malignant Progression of Laryngeal Dysplasia
Laryngeal dysplasia (LD) is the principal precursor of laryngeal squamous cell carcinoma (LSCC), but reliable biomarkers predicting malignant transformation remain unavailable. This study investigated programmed death-ligand 1 (PD-L1) expression and immune microenvironment remodeling during laryngeal carcinogenesis. Immunohistochemical analysis of PD-L1, CD4, CD8, CD68, and CD163 was performed in 36 benign lesions, 41 LDs, and 102 LSCCs. PD-L1 expression was assessed using the combined positive score (CPS) and tumor proportion score (TPS), while immune cell infiltration was quantified in the intraepithelial and stromal compartments and across the entire tissue specimen. PD-L1 expression and infiltration of all investigated immune cell populations increased progressively from benign lesions through dysplasia to invasive carcinoma. High-grade dysplasia exhibited significantly greater CD4 infiltration in all compartments and increased stromal CD8 and CD163 infiltration than low-grade dysplasia. PD-L1 expression positively correlated with intraepithelial CD163 and stromal CD8 infiltration. Although no biomarker independently distinguished progressive from non-progressive dysplasia, overall CD4, intraepithelial and overall CD68, and stromal CD163 were associated with progression risk. Immune microenvironment remodeling begins during the dysplastic stage of laryngeal carcinogenesis. These findings may improve risk stratification of laryngeal dysplasia and support the development of immunopreventive and immune-targeted therapeutic strategies.
- Open Access
Metastasizing Pleomorphic Adenoma: A Systematic Review and Pooled Case-Report Analysis
Background/Objectives: Metastasizing pleomorphic adenoma (MPA) is a rare salivary gland tumor characterized by benign pleomorphic adenoma morphology despite regional or distant metastatic behavior. Because most evidence derives from case reports and small series, this systematic review and pooled case-report analysis aimed to summarize published patient-level data and to explore clinicopathologic features, metastatic distribution, treatment, and survival without inferring causal treatment effects. Methods: PubMed, Scopus, Google Scholar, and reference lists were searched for English-language reports published up to 1 August 2025. Eligible reports described primary pleomorphic adenoma and metastatic disease reported as MPA with benign morphology; carcinoma ex pleomorphic adenoma and other malignant pleomorphic adenoma variants were excluded. The primary pooled analysis was restricted to 122 published case-report patients. Institutional cases are presented separately as illustrative cases and were not included in the primary pooled statistical analyses. Unknown, not reported, NA, and unclear values were treated as missing, and denominators are reported. Because only 16 deaths were available, survival analyses were exploratory and no multivariable Cox model was fitted. No formal risk-of-bias or certainty-of-evidence assessment was performed. Results: In the 122 published patients, sex was available for 121 patients and 71/121 (58.7%) were female. Primary tumors most frequently arose in the parotid gland (92/122, 75.4%), followed by the submandibular gland (15/122, 12.3%) and palate/soft palate (10/122, 8.2%). The median interval between primary pleomorphic adenoma and MPA was 12 years (IQR 7–21; range 0–69; n = 118). Metastatic site was reported in 120 patients and was non-mutually exclusive: bone/skeleton and lymph nodes/neck were each reported in 42/120 patients (35.0%), followed by lung/pulmonary metastases in 31/120 (25.8%). Treatment information was available for 98/122 patients. MPA-directed surgery was performed in 86/98 patients with available treatment information (87.75%). The non-surgical cohort received radiotherapy, chemotherapy, palliative treatment, treatment refusal, observation, or other non-surgical strategies. A total of 72 patients had complete covariate data for the reported Cox analyses, including 16 deaths. Estimated 1- and 5-year overall survival were 89.97% and 66.2%, respectively. Surgery was associated with improved overall survival in exploratory Kaplan–Meier comparison (log-rank p = 0.008) and univariable Cox analysis (HR 0.119, 95% CI 0.018–0.810, p = 0.030), but this association should not be interpreted as causal. Conclusions: MPA remains difficult to predict and the available evidence is limited by case-report design, missing data, publication bias, and heterogeneous follow-up. Surgical management may be considered in selected patients when technically feasible and clinically appropriate, but the observed survival association is exploratory and may be influenced by selection bias and disease characteristics. Multicenter registries, standardized reporting, centralized pathology review, molecular characterization, and longer follow-up are needed.
Open AccessMetastasizing Pleomorphic Adenoma: A Systematic Review and Pooled Case-Report Analysis
Background/Objectives: Metastasizing pleomorphic adenoma (MPA) is a rare salivary gland tumor characterized by benign pleomorphic adenoma morphology despite regional or distant metastatic behavior. Because most evidence derives from case reports and small series, this systematic review and pooled case-report analysis aimed to summarize published patient-level data and to explore clinicopathologic features, metastatic distribution, treatment, and survival without inferring causal treatment effects. Methods: PubMed, Scopus, Google Scholar, and reference lists were searched for English-language reports published up to 1 August 2025. Eligible reports described primary pleomorphic adenoma and metastatic disease reported as MPA with benign morphology; carcinoma ex pleomorphic adenoma and other malignant pleomorphic adenoma variants were excluded. The primary pooled analysis was restricted to 122 published case-report patients. Institutional cases are presented separately as illustrative cases and were not included in the primary pooled statistical analyses. Unknown, not reported, NA, and unclear values were treated as missing, and denominators are reported. Because only 16 deaths were available, survival analyses were exploratory and no multivariable Cox model was fitted. No formal risk-of-bias or certainty-of-evidence assessment was performed. Results: In the 122 published patients, sex was available for 121 patients and 71/121 (58.7%) were female. Primary tumors most frequently arose in the parotid gland (92/122, 75.4%), followed by the submandibular gland (15/122, 12.3%) and palate/soft palate (10/122, 8.2%). The median interval between primary pleomorphic adenoma and MPA was 12 years (IQR 7–21; range 0–69; n = 118). Metastatic site was reported in 120 patients and was non-mutually exclusive: bone/skeleton and lymph nodes/neck were each reported in 42/120 patients (35.0%), followed by lung/pulmonary metastases in 31/120 (25.8%). Treatment information was available for 98/122 patients. MPA-directed surgery was performed in 86/98 patients with available treatment information (87.75%). The non-surgical cohort received radiotherapy, chemotherapy, palliative treatment, treatment refusal, observation, or other non-surgical strategies. A total of 72 patients had complete covariate data for the reported Cox analyses, including 16 deaths. Estimated 1- and 5-year overall survival were 89.97% and 66.2%, respectively. Surgery was associated with improved overall survival in exploratory Kaplan–Meier comparison (log-rank p = 0.008) and univariable Cox analysis (HR 0.119, 95% CI 0.018–0.810, p = 0.030), but this association should not be interpreted as causal. Conclusions: MPA remains difficult to predict and the available evidence is limited by case-report design, missing data, publication bias, and heterogeneous follow-up. Surgical management may be considered in selected patients when technically feasible and clinically appropriate, but the observed survival association is exploratory and may be influenced by selection bias and disease characteristics. Multicenter registries, standardized reporting, centralized pathology review, molecular characterization, and longer follow-up are needed.
- Open Access
Significance of PD-L1 and Tumor Microenvironment in Laryngeal Squamous Cell Cancer
Background: Despite the considerable advancement in the field of medicine over recent decades, laryngeal cancer continues to be a challenge. The field of immune oncology has generated promising immunomodulation therapies and opened up new ways of treatment. Methods: Our retrospective study included 102 patients diagnosed with laryngeal squamous cell cancer (LSCC). Immunohistochemistry was used to evaluate the expression of PD-L1 and tumor microenvironment cells (CD4, CD8, CD68 and CD163). Results: PD-L1 expression showed statistically significant positive correlations with all examined tumor microenvironment cells. Patients with high CD68 and CD163 expression intratumorally (p = 0.0005 and p = 0.006, respectively) had statistically significant shorter disease-specific survival. Moreover, a statistically shorter time to recurrence was found in patients with high CD68 intratumoral and CD8 overall counts (p = 0.049 and p = 0.019, respectively). Also, high CD8 overall (>23%) and CD68 intratumoral (>2.7%) expression were statistically significant predictors of recurrence (p = 0.028, OR = 3.11 and p = 0.019, OR = 3.13, respectively). Conclusions: Higher CD68 and CD163 expression represented significantly worse prognosticators for clinical outcomes in patients with LSCC. In order to determine which LSCC patients will benefit from anti-PD-1/PD-L1 inhibitors, it is crucial to elucidate the relationship between PD-L1 expression, immune cell distribution and prognosis in LSCC patients.
Open AccessSignificance of PD-L1 and Tumor Microenvironment in Laryngeal Squamous Cell Cancer
Background: Despite the considerable advancement in the field of medicine over recent decades, laryngeal cancer continues to be a challenge. The field of immune oncology has generated promising immunomodulation therapies and opened up new ways of treatment. Methods: Our retrospective study included 102 patients diagnosed with laryngeal squamous cell cancer (LSCC). Immunohistochemistry was used to evaluate the expression of PD-L1 and tumor microenvironment cells (CD4, CD8, CD68 and CD163). Results: PD-L1 expression showed statistically significant positive correlations with all examined tumor microenvironment cells. Patients with high CD68 and CD163 expression intratumorally (p = 0.0005 and p = 0.006, respectively) had statistically significant shorter disease-specific survival. Moreover, a statistically shorter time to recurrence was found in patients with high CD68 intratumoral and CD8 overall counts (p = 0.049 and p = 0.019, respectively). Also, high CD8 overall (>23%) and CD68 intratumoral (>2.7%) expression were statistically significant predictors of recurrence (p = 0.028, OR = 3.11 and p = 0.019, OR = 3.13, respectively). Conclusions: Higher CD68 and CD163 expression represented significantly worse prognosticators for clinical outcomes in patients with LSCC. In order to determine which LSCC patients will benefit from anti-PD-1/PD-L1 inhibitors, it is crucial to elucidate the relationship between PD-L1 expression, immune cell distribution and prognosis in LSCC patients.
- Open Access
- 21 March 2024
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 90 (4) , 101425
Internal jugular vein thrombosis caused by invasive pharyngeal cancer: a case report and literature review
- 21 March 2024
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 90 (4) , 101425
Open AccessInternal jugular vein thrombosis caused by invasive pharyngeal cancer: a case report and literature review
- Open Access
- 31 May 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (6) , 927
Long-Term Care and Follow-Up in Laryngeal Cancer Patients: A Multicenter Retrospective Analysis
Purpose: We conducted an outcome analysis on surgically treated laryngeal squamous cell carcinoma (LSCC) patients. Methods: A multicenter retrospective study with 352 patients was analyzed. A new nomogram that incorporates age, T- and N-classification, and treatment was created. Results: Recurrence was observed in 65 (18.5%) patients after a mean time of 16.5 months. After 60 months, 91 (25.9%) of patients developed secondary primary tumors (SPT), most commonly in the lungs (n = 29; 8.2%) followed by other head and neck cancers (n = 21; 6.0%). Notably, the mean time to occurrence of secondary head and neck cancers was twice that of lung cancer (101.1 vs. 47.5 months). Conclusion: Recurrent disease is less common in LSCC patients and appears much earlier than SPT. Because one in every four laryngeal cancer patients develops SPTs within 5–10 years, long-term care and follow-up, including imaging studies, are highly recommended. The nomogram was useful for estimating survival.
- 31 May 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (6) , 927
Open AccessLong-Term Care and Follow-Up in Laryngeal Cancer Patients: A Multicenter Retrospective Analysis
Purpose: We conducted an outcome analysis on surgically treated laryngeal squamous cell carcinoma (LSCC) patients. Methods: A multicenter retrospective study with 352 patients was analyzed. A new nomogram that incorporates age, T- and N-classification, and treatment was created. Results: Recurrence was observed in 65 (18.5%) patients after a mean time of 16.5 months. After 60 months, 91 (25.9%) of patients developed secondary primary tumors (SPT), most commonly in the lungs (n = 29; 8.2%) followed by other head and neck cancers (n = 21; 6.0%). Notably, the mean time to occurrence of secondary head and neck cancers was twice that of lung cancer (101.1 vs. 47.5 months). Conclusion: Recurrent disease is less common in LSCC patients and appears much earlier than SPT. Because one in every four laryngeal cancer patients develops SPTs within 5–10 years, long-term care and follow-up, including imaging studies, are highly recommended. The nomogram was useful for estimating survival.
- Open Access
- 21 December 2022
- Published by Opca bolnica Zadar in Medica Jadertina
- Vol. 52 (3) , 171-177
Funkcionalni i onkološki ishodi bolesnika liječenih frontolateralnom laringektomijom
Cilj rada: Analizirati funkcionalni i onkološki ishod bolesnika s ranim stadijem karcinoma grkljana, liječenih frontolateralnom laringektomijom. Bolesnici i metode: U retrospektivno istraživanje uključeno je 45 kirurški liječenih bolesnika s ranim...
- 21 December 2022
- Published by Opca bolnica Zadar in Medica Jadertina
- Vol. 52 (3) , 171-177
Open AccessFunkcionalni i onkološki ishodi bolesnika liječenih frontolateralnom laringektomijom
Cilj rada: Analizirati funkcionalni i onkološki ishod bolesnika s ranim stadijem karcinoma grkljana, liječenih frontolateralnom laringektomijom. Bolesnici i metode: U retrospektivno istraživanje uključeno je 45 kirurški liječenih bolesnika s ranim...
- Open Access
IMP3 Protein Overexpression Is Linked to Unfavorable Outcome in Laryngeal Squamous Cell Carcinoma
Background: The aim of this study was to (i) determine IMP3 protein expression in benign and malignant laryngeal lesions, (ii) compare its expression to Ki-67, p53, cyclin D1, and (iii) finally, to examine the prognostic power of IMP3 in squamous cell carcinomas of the larynx (LSSC). Methods: IMP3 protein expression was evaluated in 145 patients, including 62 LSCC, 45 dysplasia (25 with low and 20 with high-grade dysplasia), and 38 benign lesions (vocal cord polyps and nodules). Results: IMP3 was significantly higher expressed in LSCC compared to dysplasia and benign lesions (p < 0.001; p < 0.001, respectively). Similarly, higher expression patterns were observed for Ki-67 and p53, whereas cyclin D1 was equally distributed in all three lesions. IMP3 (p = 0.04) and Ki-67 (p = 0.02) expressions were significantly linked to neck node positivity, and IMP3 overexpression to worse disease-specific survival (p = 0.027). Conclusion: Since IMP3 showed significantly higher expression in laryngeal carcinomas, but not in high- or low-grade dysplasia, it serves as a useful marker to differentiate between invasive and noninvasive lesions. Higher IMP3 expression represented a significantly worse prognosticator for clinical outcomes of patients with squamous cell carcinoma of the larynx.
Open AccessIMP3 Protein Overexpression Is Linked to Unfavorable Outcome in Laryngeal Squamous Cell Carcinoma
Background: The aim of this study was to (i) determine IMP3 protein expression in benign and malignant laryngeal lesions, (ii) compare its expression to Ki-67, p53, cyclin D1, and (iii) finally, to examine the prognostic power of IMP3 in squamous cell carcinomas of the larynx (LSSC). Methods: IMP3 protein expression was evaluated in 145 patients, including 62 LSCC, 45 dysplasia (25 with low and 20 with high-grade dysplasia), and 38 benign lesions (vocal cord polyps and nodules). Results: IMP3 was significantly higher expressed in LSCC compared to dysplasia and benign lesions (p < 0.001; p < 0.001, respectively). Similarly, higher expression patterns were observed for Ki-67 and p53, whereas cyclin D1 was equally distributed in all three lesions. IMP3 (p = 0.04) and Ki-67 (p = 0.02) expressions were significantly linked to neck node positivity, and IMP3 overexpression to worse disease-specific survival (p = 0.027). Conclusion: Since IMP3 showed significantly higher expression in laryngeal carcinomas, but not in high- or low-grade dysplasia, it serves as a useful marker to differentiate between invasive and noninvasive lesions. Higher IMP3 expression represented a significantly worse prognosticator for clinical outcomes of patients with squamous cell carcinoma of the larynx.
- 16 June 2021
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 34 (5) , e15029
Giant rhinophyma with olfactory and breathing dysfunction successfully treated by shave excision and electrocautery
Click on the article title to read more.
- 16 June 2021
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 34 (5) , e15029
Giant rhinophyma with olfactory and breathing dysfunction successfully treated by shave excision and electrocautery
Click on the article title to read more.